Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1D | O15297 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL839867 | 0.84 | PPM1D (0.33) | PPM1D | |
| SCHEMBL22470143 | 0.78 | PPM1D (0.33) | PPM1D | |
| SCHEMBL22470145 | 0.78 | PPM1D (0.33) | PPM1D | |
| SCHEMBL3568839 | 0.77 | PPM1D (0.37) | PPM1D | |
| SCHEMBL838814 | 0.75 | PPM1D (0.35) | PPM1D | |
| SCHEMBL3126788 | 0.75 | PPM1D (0.35) | PPM1D | |
| SCHEMBL18980367 | 0.73 | PPM1D (0.38) | PPM1D | |
| SCHEMBL14936099 | 0.72 | PPM1D (0.36) | PPM1D | |
| Trifluoroacetic Acid SCHEMBL14761460 | 0.71 | PPM1D (0.34) | PPM1D | |
| SCHEMBL1003539 | 0.71 | PIK3CD (0.36) | PPM1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059157-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2025-02-20 | — | — | US | disclosed |
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2023-09-28 | — | — | US | disclosed |
| US-11629134-B2 | TLR7/8 antagonists and uses thereof | MERCK PATENT GMBH (DE) | 2023-04-18 | — | — | US | disclosed |
| CN-108699032-B | Polycyclic TLR7/8 antagonists and their use in the treatment of immune disorders | 默克专利有限公司 | 2022-07-22 | — | — | CN | disclosed |
| CN-113603675-A | Polycyclic TLR7/8 antagonists and their use in the treatment of immune disorders | 默克专利有限公司 | 2021-11-05 | — | — | CN | disclosed |
| EP-3889146-A1 | POLYHETEROCYCLIC TLR7/8 ANTAGONISTS AND THEIR USES FOR TREATING IMMUNE DISORDERS | Merck Patent GmbH (DE) | 2021-10-06 | — | — | EP | disclosed |
| EP-3889145-A1 | 8-CYANO-5-PIPERIDINO-QUINOLINES AS TLR7/8 ANTAGONISTS AND THEIR USES FOR TREATING IMMUNE DISORDERS | Merck Patent GmbH (DE) | 2021-10-06 | — | — | EP | disclosed |
| US-20210115013-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-04-22 | — | — | US | disclosed |
| US-10947213-B1 | TLR7/8 antagonists and uses thereof | MERCK PATENT GMBH (DE) | 2021-03-16 | — | — | US | disclosed |
| US-10696649-B2 | TLR7/8 antagonists and uses thereof | MERCK PATENT GMBH (DE) | 2020-06-30 | — | — | US | disclosed |
| US-20200095222-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2020-03-26 | — | — | US | disclosed |
| US-10544122-B2 | TLR7/8 antagonists and uses thereof | MERCK PATENT GMBH (DE) | 2020-01-28 | — | — | US | disclosed |
| US-20190330183-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-10-31 | — | — | US | disclosed |
| US-10399957-B2 | TLR7/8 antagonists and uses thereof | MERCK PATENT GMBH (DE) | 2019-09-03 | — | — | US | disclosed |
| EP-3390389-A1 | POLYCYCLIC TLR7/8 ANTAGONISTS AND USE THEREOF IN THE TREATMENT OF IMMUNE DISORDERS | Merck Patent GmbH (DE) | 2018-10-24 | — | — | EP | disclosed |
| US-20170174653-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-06-22 | — | — | US | disclosed |
| WO-2017106607-A1 | POLYCYCLIC TLR7/8 ANTAGONISTS AND USE THEREOF IN THE TREATMENT OF IMMUNE DISORDERS | MERCK PATENT GMBH (DE) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | PPM1D 2653/4885ALDH1A1 2648/4885SLC6A9 4501/4885 |
| US-20190330183-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | PPM1D 2653/4885ALDH1A1 2648/4885SLC6A9 4501/4885 |
| US-11629134-B2 | TLR7/8 antagonists and uses thereof | TLR7, TLR8, TLR9 | PPM1D 2653/4885ALDH1A1 2648/4885SLC6A9 4501/4885 |
| US-20210115013-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | PPM1D 2930/4885ALDH1A1 2896/4885SLC6A9 4378/4885 |
| US-10947213-B1 | TLR7/8 antagonists and uses thereof | TLR7, TLR8, TLR9 | PPM1D 2653/4885ALDH1A1 2648/4885SLC6A9 4501/4885 |
| US-10544122-B2 | TLR7/8 antagonists and uses thereof | TLR7, TLR8, TLR9 | PPM1D 2653/4885ALDH1A1 2648/4885SLC6A9 4501/4885 |
| US-20200095222-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | PPM1D 2653/4885ALDH1A1 2648/4885SLC6A9 4501/4885 |
| US-20250059157-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | PPM1D 2653/4885ALDH1A1 2648/4885SLC6A9 4501/4885 |
| US-10399957-B2 | TLR7/8 antagonists and uses thereof | TLR7, TLR8, TLR9 | PPM1D 2813/4885ALDH1A1 2465/4885SLC6A9 4489/4885 |
| US-20170174653-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | PPM1D 2813/4885ALDH1A1 2465/4885SLC6A9 4489/4885 |
| US-10696649-B2 | TLR7/8 antagonists and uses thereof | TLR7, TLR8, TLR9 | PPM1D 2653/4885ALDH1A1 2648/4885SLC6A9 4501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.